These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 30629620

  • 1. Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program.
    Richter L, Schmid D, Kanitz EE, Zwazl I, Pöllabauer E, Jasinska J, Burgmann H, Kundi M, Wiedermann U.
    PLoS One; 2019; 14(1):e0210081. PubMed ID: 30629620
    [Abstract] [Full Text] [Related]

  • 2. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland.
    Rinta-Kokko H, Palmu AA, Auranen K, Nuorti JP, Toropainen M, Siira L, Virtanen MJ, Nohynek H, Jokinen J.
    Vaccine; 2018 Apr 05; 36(15):1934-1940. PubMed ID: 29526371
    [Abstract] [Full Text] [Related]

  • 3. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil.
    Brandileone MC, Almeida SCG, Minamisava R, Andrade AL.
    Vaccine; 2018 May 03; 36(19):2559-2566. PubMed ID: 29650385
    [Abstract] [Full Text] [Related]

  • 4. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme.
    Ingels H, Rasmussen J, Andersen PH, Harboe ZB, Glismann S, Konradsen H, Hoffmann S, Valentiner-Branth P, Lambertsen L, Danish Pneumococcal Surveillance Collaboration Group 2009-2010.
    Vaccine; 2012 Jun 06; 30(26):3944-50. PubMed ID: 22504662
    [Abstract] [Full Text] [Related]

  • 5. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, McIntyre P.
    Clin Infect Dis; 2017 Jan 15; 64(2):175-183. PubMed ID: 27986682
    [Abstract] [Full Text] [Related]

  • 6. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.
    Vaccine; 2013 Dec 16; 31(52):6232-8. PubMed ID: 24176490
    [Abstract] [Full Text] [Related]

  • 7. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study.
    Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A, Mturi N, Moisi JC, Adetifa IM, Karani A, Akech DO, Otiende M, Bwanaali T, Wafula J, Mataza C, Mumbo E, Tabu C, Knoll MD, Bauni E, Marsh K, Williams TN, Kamau T, Sharif SK, Levine OS, Scott JAG.
    Lancet; 2019 May 25; 393(10186):2146-2154. PubMed ID: 31000194
    [Abstract] [Full Text] [Related]

  • 8. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study.
    Desmet S, Lagrou K, Wyndham-Thomas C, Braeye T, Verhaegen J, Maes P, Fieuws S, Peetermans WE, Blumental S.
    Lancet Infect Dis; 2021 Jan 25; 21(1):127-136. PubMed ID: 32702303
    [Abstract] [Full Text] [Related]

  • 9. Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil.
    Reis JN, Azevedo J, de Oliveira AML, Menezes APO, Pedrosa M, Dos Santos MS, Ribeiro LC, Freitas HF, Gouveia EL, Teles MB, Carvalho MDG, Reis MG, Nascimento-Carvalho C, Verani JR.
    Vaccine; 2024 Jan 25; 42(3):591-597. PubMed ID: 38184393
    [Abstract] [Full Text] [Related]

  • 10. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P, Lefebvre B, Deceuninck G, Longtin J.
    Vaccine; 2018 Jan 08; 36(3):421-426. PubMed ID: 29224962
    [Abstract] [Full Text] [Related]

  • 11. Invasive disease potential of Streptococcus pneumoniae serotypes before and after 10-valent pneumococcal conjugate vaccine introduction in a rural area, southern Mozambique.
    Massora S, Lessa FC, Moiane B, Pimenta FC, Mucavele H, Chaúque A, Cossa A, Verani JR, Tembe N, da Gloria Carvalho M, Muñoz-Almagro C, Sigaúque B.
    Vaccine; 2019 Dec 03; 37(51):7470-7477. PubMed ID: 31575493
    [Abstract] [Full Text] [Related]

  • 12. Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study.
    Choi YH, Andrews N, Miller E.
    PLoS Med; 2019 Jul 03; 16(7):e1002845. PubMed ID: 31269018
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.
    Jayasinghe S, Chiu C, Menzies R, Lehmann D, Cook H, Giele C, Krause V, McIntyre P.
    Vaccine; 2015 Nov 27; 33(48):6666-74. PubMed ID: 26519550
    [Abstract] [Full Text] [Related]

  • 14. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution.
    Izurieta P, Bahety P, Adegbola R, Clarke C, Hoet B.
    Expert Rev Vaccines; 2018 Jun 27; 17(6):479-493. PubMed ID: 29241390
    [Abstract] [Full Text] [Related]

  • 15. Streptococcus pneumoniae serotype 19A: worldwide epidemiology.
    Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert RR, Jodar L.
    Expert Rev Vaccines; 2017 Oct 27; 16(10):1007-1027. PubMed ID: 28783380
    [Abstract] [Full Text] [Related]

  • 16. Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015.
    Wagenvoort GH, Sanders EA, Vlaminckx BJ, de Melker HE, van der Ende A, Knol MJ.
    Euro Surveill; 2017 Mar 09; 22(10):. PubMed ID: 28300529
    [Abstract] [Full Text] [Related]

  • 17. Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands.
    Peckeu L, van der Ende A, de Melker HE, Sanders EAM, Knol MJ.
    Vaccine; 2021 Jan 08; 39(2):431-437. PubMed ID: 33243632
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations.
    Naucler P, Galanis I, Morfeldt E, Darenberg J, Örtqvist Å, Henriques-Normark B.
    Clin Infect Dis; 2017 Nov 13; 65(11):1780-1789. PubMed ID: 29020171
    [Abstract] [Full Text] [Related]

  • 19. Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation.
    dos Santos SR, Passadore LF, Takagi EH, Fujii CM, Yoshioka CR, Gilio AE, Martinez MB.
    Vaccine; 2013 Dec 09; 31(51):6150-4. PubMed ID: 23747454
    [Abstract] [Full Text] [Related]

  • 20. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E, Albert MJ.
    Vaccine; 2012 Dec 31; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.